Strategies to expand access to naloxone (Narcan) for the prevention of opioid overdoses were explored during a webinar hosted by the Reagan-Udall Foundation for the FDA on Tuesday.
Over 100,000 people died from drug overdoses over a 12-month period ending in April 2021, according to CDC's provisional data.
The topic for this month's Therapeutics/Vaccines Lab Meeting is "Test to Treat."
This is our once-monthly COVID-19 Evidence Accelerator Therapeutics/Vaccines Lab Meeting. This meeting is held the third Thursday of every month at 3pm ET.
If you are interested in joining the meeting series please email us at evidenceaccelerator@reaganudall.org.
This month's Diagnostics Lab meeting we will look at LAMP-based diagnostics; Testing in the airline industry and air travel. We will hear presentations from Dr. Nilay Shah of Delta Airlines and Randy True of FloodLamp Biotechnologies.
This is the once-monthly COVID-19 Evidence Accelerator Diagnostics Lab Meeting. These meetings occur the third Thursday of every month at 12 pm ET.
If you are interested in attending the meeting series please email evidenceaccelerator@reaganudall.org.
FDA and the Reagan-Udall Foundation will hold a virtual meeting on March 29 to discuss strategies to increase access to naloxone, the opioid overdose reversal drug.
Read the full story here.
What: The Reagan-Udall Foundation for the FDA (FDA Foundation), in collaboration with the U.S. Food and Drug Administration, is hosting a virtual public meeting to explore questions about access to naloxone, a drug used to reverse opioid overdoses. Harm reduction specialists, physicians, pharmacists, and regulators will share their experiences in addressing the availability of this life-saving medication for heroin, fentanyl, and prescription opioid overdose. Significant time is set aside to allow public comment for up to 30 people (pre-registration required).
